IMMU Immunomedics Inc.

10.88
-0.29  -3%
Previous Close 11.17
Open 11.29
Price To book -27.90
Market Cap 1645981333
Shares 151,285,049
Volume 2,499,228
Short Ratio 10.43
Av. Daily Volume 3,043,401

SEC filingsSee all SEC filings

  1. UPLOAD [Cover] - SEC-generated letter
  2. 8-K/A [Amend] - Current report 171103144
  3. 8-K - Current report 171096180
  4. 424B3 - Prospectus [Rule 424(b)(3)] 171095888
  5. EFFECT - Notice of Effectiveness 171093196

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 interim data at ESMO September 10, 2017.
SACITUZUMAB GOVITECAN
Urothelial cancer
Phase 3 enrollment due to commence early 4Q 2017. BLA filing due between December 2017 and March 2018. Phase 2 data to be used for accelerated approval.
SACTUZUMAB GOVITECAN (IMMU-132)
Cancer - metastatic triple-negative breast cancer
Phase 2 update provided at ASCO June 2016. Ongoing through 2017.
SACITUZUMAB GOVITECAN
Non-small cell lung cancer (NSCLC)
Phase 2 interim data presented April 2016
Labetuzumab govitecan
Metastatic colorectal cancer (mCRC)
Phase 3 trial terminated due to poor efficacy
Clivatuzumab tetraxetan
Cancer - Pancreatic
Endpoints not met July 2015
Epratuzumab (EMBODY 1 and 2)
Lupus

Latest News

  1. Edited Transcript of IMMU earnings conference call or presentation 16-Aug-17 9:00pm GMT
  2. ETFs with exposure to Immunomedics, Inc. : October 3, 2017
  3. Why Carnival, Immunomedics, and Fitbit Slumped Today
  4. Immunomedics Announces Agreements to Exchange Approximately $80.0 Million of Its 4.75% Convertible Senior Notes Due 2020 for Common Stock
  5. Are Options Traders Betting on a Big Move in Immunomedics (IMMU) Stock?
  6. Immunomedics Presents Interim Phase 2 Results With Sacituzumab Govitecan (IMMU-132) in Patients With Pretreated Metastatic Urothelial Cancer
  7. Immunomedics to Participate in Upcoming Investor Conferences
  8. ETFs with exposure to Immunomedics, Inc. : August 28, 2017
  9. Here's Why Immunomedics Rose as Much as 14.2% Today
  10. Immunomedics, Inc. :IMMU-US: Earnings Analysis: Q4, 2017 By the Numbers : August 24, 2017
  11. Immunomedics (IMMU) Catches Eye: Stock Up 5.1%
  12. Zacks.com featured highlights: Glu Mobile, Calumet Specialty Products Partners, The Bancorp, Immunomedics and Hudbay Minerals
  13. Immunomedics' Progress in Phase II Cancer Study Encouraging
  14. Immunomedics, Inc. breached its 50 day moving average in a Bullish Manner : IMMU-US : August 22, 2017
  15. Immunomedics, Inc. :IMMU-US: Earnings Analysis: 2017 By the Numbers : August 21, 2017
  16. Immunomedics Announces Publication of Phase 2 Results With Labetuzumab Govitecan (IMMU-130) That Demonstrate Promising Efficacy as a Single Agent in Patients With Metastatic Colorectal Cancer
  17. Immunomedics, Inc. – Value Analysis (NASDAQ:IMMU) : August 17, 2017
  18. Immunomedics reports 4Q loss
  19. Immunomedics Announces Fiscal 2017 Results and Strategic Developments; Reiterates Guidance on BLA Submission Timeline

SEC Filings

  1. UPLOAD [Cover] - SEC-generated letter
  2. 8-K/A [Amend] - Current report 171103144
  3. 8-K - Current report 171096180
  4. 424B3 - Prospectus [Rule 424(b)(3)] 171095888
  5. EFFECT - Notice of Effectiveness 171093196
  6. CT ORDER - Confidential treatment order 171091175
  7. CORRESP [Cover] - Correspondence
  8. S-3/A [Amend] - Registration statement under Securities Act of 1933 171090583
  9. 10-K/A [Amend] - Annual report [Section 13 and 15(d), not S-K Item 405] 171090172
  10. 10-Q/A [Amend] - Quarterly report [Sections 13 or 15(d)] 171090138